Contact Us
Contact Us
hello@tetratherix.com

Different needs. Different leading partnerships. Same Biostealth propositions defined by trends of modern medicine

We’ve designed a portfolio of products that have been developed to disrupt multiple market segments. Our technical approach is focused on real clinical utility. Our supply and manufacturing strategy is centred on usage at scale.

We commercialise the Tetramatrix platform via licensing for multiple parallel applications

We generate revenue through a combination of IP license fees and product supply, the proportions of which can be flexible depending on the requirements in market segments.

Market Validation
Our partnerships send a positive signal to our current and prospective employees, partners and investors that the Tetramatrix platform is attractive to experts in our chosen segments.
Execution Capacity
We partner early with global leaders to utilise their infrastructure. This helps us scale faster, and we efficiently win market share together by utilising their established infrastructure.
Long Term Efficiencies
Our partnerships are deliberately long term co-development agreements given our SaaS style platform model allows parallel development and enables efficiencies in RandD, manufacturing and IP strategies.
80/20 Model
We implement the 80:20 concept: we have completed the foundational safety, efficacy and manufacturing with the remaining 20% completed by the partner, facilitating rapid path to market.

“TTRX provides a unique exposure to a biomed business with the scale and profitability of a SaaS platform, the likes of which reminds me of Xero in the early days”

Rod Drury - Xero Founder and Tetratherix Investor

Parallel platforms provide us flexibility to partner at earlier stages with accretive returns that compound over time

Similar to a ‘build-to-buy’ model, we partner differently to, and at earlier stages than, traditional medtech opportunities. Our return profile is different and not built on unilateral M&A. Smaller return at early stages but compounds to a far greater return over time.

Partnering that scales quickly, limits risk and builds long term sustainability

Pilot Clinical Trial
Endpoints and assessment details are verified with partners prior to running Pilot Clinical Trials. Aligning objectives at this point ensures the data from a desired clinical trial is rapidly translated. This stage of validation is still controlled and [mostly] funded by Tetratherix.
Pivotal Clinical Trial
Using the partner’s network and market access facilitates multi-centre trials and fast recruitment to complete the required package. The engagement of clinicians in trials is used by market leaders to engage with their customers to maintain loyalty across their portfolio(s).
Regulatory Approval
The long term engagement between the two entities allows merging of the two quality systems to share design files, verification and product validation. This speeds up the regulatory process and the growing approval stack in major markets provide future reference points.

Our Flywheel model

We gain significant momentum through consistent, shared efforts that build upon each other. Now in motion, our flywheel’s momentum will help drive sustained and compounding growth with less effort over time.

Second model

We gain significant momentum through consistent, shared efforts that build upon each other. Now in motion, our flywheel’s momentum will help drive sustained and compounding growth with less effort over time.
1 / 3